Huadong Medicine Co., Ltd
000963
Rank in Stocks
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
Share Price
$3.89
Market Cap
$6.83B
Change (1 day)
-2.22%
Change (1 year)
-30.58%
Country
CN
Trade Huadong Medicine Co., Ltd (000963)
Category
Healthcare
Revenue for Huadong Medicine Co., Ltd (000963)
Revenue in Jun 2026 TTM: $6.59B
According to Huadong Medicine Co., Ltd latest financial reports the company's current revenue (TTM) is $6.59B. In 2024 the company made a revenue of $5.74B an increase over the revenue in the year 2023 that was $5.74B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Huadong Medicine Co., Ltd from 2001 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $6.59B | 5.71% |
| 2025 | $6.23B | 8.57% |
| 2024 | $5.74B | 0.04% |
| 2023 | $5.74B | 4.96% |
| 2022 | $5.47B | 0.54% |
| 2021 | $5.44B | 5.47% |
| 2020 | $5.16B | 1.29% |
| 2019 | $5.09B | 14.19% |
| 2018 | $4.46B | 4.21% |
| 2017 | $4.28B | 17.02% |
| 2016 | $3.66B | 9.25% |
| 2015 | $3.35B | 9.38% |
| 2014 | $3.06B | 10.99% |
| 2013 | $2.76B | 17.88% |
| 2012 | $2.34B | 32.41% |
| 2011 | $1.77B | 29.90% |
| 2010 | $1.36B | 18.60% |
| 2009 | $1.15B | 29.99% |
| 2008 | $881.72M | 32.65% |
| 2007 | $664.70M | 30.76% |
| 2006 | $508.34M | 17.77% |
| 2005 | $431.65M | 23.93% |
| 2004 | $348.31M | 23.94% |
| 2003 | $281.03M | 12.60% |
| 2002 | $249.58M | 9.48% |
| 2001 | $227.97M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 0.34% |
IN
|
